<DOC>
	<DOCNO>NCT01036087</DOCNO>
	<brief_summary>The goal clinical research study learn effective combination chemotherapy include panitumumab , Abraxane ( nab-paclitaxel ) , carboplatin ( PNC ) fluorouracil , epirubicin , cyclophosphamide ( FEC ) use surgery treatment IBC . The safety PNC combination also study .</brief_summary>
	<brief_title>Panitumumab , Nab-paclitaxel Carboplatin HER2 Negative Inflammatory Breast Cancer</brief_title>
	<detailed_description>Study Drugs : Panitumumab design prevent slow growth tumor cell block protein surface cancer cell , call epidermal growth factor receptor ( EGFR ) . Nab-paclitaxel design kill tumor cell bind chemotherapy drug paclitaxel albumin , protein make liver . The albumin get cancer cell release paclitaxel directly tumor . Carboplatin design stop slow cancer cell grow damage RNA DNA ( genetic material cell ) tell tumor cell grow . 5-fluorouracil , epirubicin , cyclophosphamide work different way stop growth tumor cell , either kill cell stop dividing . Study Drug Administration : On Day 1 Week 1 , receive panitumumab needle vein 60 minute . After Week 1 , receive total 4 cycle PNC . Each cycle 4 week . During Cycles 1-3 ( Weeks 2-13 ) , receive PNC vein week 3 week , follow week rest . You receive PNC needle vein . The infusion take 90 minute . During Cycle 4 ( Week 14 17 ) , receive PNC Day 1 Weeks 14 15 . On Day 1 Week 16 , receive carboplatin nab-paclitaxel . Starting Day 1 Week 18 , receive FEC needle vein . The infusion take 90 minute . You receive total 4 cycle , 3 week long , 12 week . Surgery : After complete PNC FEC treatment , standard care surgery perform . You give separate consent form read sign . During surgery , breast tissue sample collect identify tumor routine procedure . Study Visits : Each week receive PNC FEC therapy , dose chemotherapy , blood ( 1 1/2 tablespoon ) draw routine test . Before Week 2 , optional breast core biopsy perform collect tumor sample biomarker test On Week 2 , every 4 week end PNC , FEC , follow test procedure perform dose chemotherapy . - You physical exam , include measurement vital sign weight , breast exam . - Blood ( 1 1/2 tablespoon ) draw routine test . - You ask well able perform normal activity daily live ( performance status ) . During Weeks 2 9 , FEC therapy , study doctor take picture breast . Before FEC ( Cycle 4 PNC ) surgery , follow test procedure perform : - To check status disease , image study include mammogram , breast MRI , breast ultrasound , digital photograph perform . - You physical exam , include vital sign , weight , breast exam - Blood ( 3 tablespoon ) draw routine test . - You ask symptom may . - The ECGs ECHO/MUGA scan repeat , doctor think necessary . This schedule may change study doctor think necessary . Length study : You may remain study treatment 10 month . You take study early disease get bad experience intolerable side effect . This investigational study . Panitumumab FDA approve commercially available treatment EGFR-expressing metastatic colorectal cancer disease progression . It 's use study consider investigational . Nab-paclitaxel FDA approve commercially available treatment breast cancer failure combination chemotherapy metastatic disease relapse within 6 month adjuvant chemotherapy . The use Nab-paclitaxel study consider investigational . Carboplatin FDA approve commercially available treatment IBC . FEC FDA approve breast cancer general , specifically inflammatory breast cancer . The use PNC FEC together surgery investigational . Up 40 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histological confirmation breast carcinoma . Pathologic evidence dermal lymphatic invasion note require . 2 . Clinical diagnosis IBC ( presence inflammatory change involve breast , include diffuse erythema , heat , ridge , peau d'orange ) . 3 . &gt; /= Age 18 4 . ECOG performance status &lt; /= 1 5 . Adequate hematologic function : Absolute neutrophil count ( ANC ) &gt; /= 1.5 x 109/L , Platelet count &gt; /= 100 x 109/L , Hemoglobin &gt; /= 9.0 g/dL 6 . Adequate cardiac function ( LVEF &gt; /= 45 % ) 7 . Adequate Renal function : Creatinine ( Cr ) &lt; /= 1.5 mg/dL x ULN , Creatinine clearance ( CrCl ) &gt; /= 50 mL/min calculate CockcroftGault method follow : Male creatinine clearance = ( 140 age ) x ( weight Kg ) / ( serum Cr x 72 ) Female CrCl = ( 140 age ) x ( weight Kg ) x 0.85 / ( serum Cr x 72 ) 8 . Adequate Hepatic function : Aspartate aminotransferase ( AST ) &lt; /= 2.5 x ULN • Alanine aminotransferase ( ALT ) &lt; /= 2.5 x ULN • Alkaline phosphatase ( Alp ) &lt; /= 2.5 x ULN.Total bilirubin &lt; /=1.5 x ULN 9 . Ability willingness sign inform consent form protocol 10 . If female childbearing potential ( woman postmenopausal &lt; 1 year , surgically sterilize , abstinent ) , pregnancy urine test negative , agree consistent correct use one follow acceptable method birth control : male partner sterile prior female subject entry study sole sexual partner female subject ; intrauterine device ( IUD ) document failure rate le 1 % per year ; oral contraception , barrier method , include diaphragm condom spermicide . 11 . Patients metastatic disease , metastatic site amendable local therapy ( i.e . radiation and/or surgery ) , candidate breast surgery eligible , 1 . History radiation chemotherapy 2 . HER2positive breast carcinoma ( IHC stain 3+ HER2 gene amplification FISH ) 3 . Recurrent breast cancer 4 . History malignancy ( except cure nonmelanomatous skin cancer cure cervical carcinoma situ , malignancy evidence disease treatment &gt; 5 year ) 5 . Known positive test ( ) human immunodeficiency virus infection , hepatitis C virus , acute chronic active hepatitis B infection 6 . History extensive interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence extensive interstitial lung disease baseline chest CT scan 7 . Patient significant medical psychiatric condition would make assessment toxicity efficacy difficult . 8 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 9 . Peripheral neuropathy &gt; = Gr II</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Inflammatory Breast Cancer</keyword>
	<keyword>IBC</keyword>
	<keyword>Primary breast carcinoma</keyword>
	<keyword>HER2 negative overexpression</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Vectibix</keyword>
	<keyword>Nab-paclitaxel</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>PNC</keyword>
	<keyword>5-fluorouracil</keyword>
	<keyword>5-FU</keyword>
	<keyword>Adrucil</keyword>
	<keyword>Efudex</keyword>
	<keyword>Epirubicin</keyword>
	<keyword>Ellence</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>FEC</keyword>
</DOC>